阿替普酶与尿激酶溶栓治疗急性脑梗死的临床疗效及安全性比较  

Comparison of Clinical Efficacy and Safety of Alteplase and Urokinase Thrombolytic Therapy for Acute Cerebral Infarction

作　　者：朱晨静 武书平 武豪杰 ZHU Chen-jing;WU Shu-ping;WU Hao-jie(Department of Neurology,Wuyang County People's Hospital,Luohe 462400,China)

机构地区：[1]舞阳县人民医院神经内科,漯河462400

出　　处：《四川解剖学杂志》2024年第2期66-68,87,共4页Sichuan Journal of Anatomy

摘　　要：目的:探讨急性脑梗死(ABI)患者应用阿替普酶与尿激酶溶栓治疗的临床疗效及安全性.方法:选取2021年5月至2023年5月本院收治的80例ABI患者为研究对象.采用随机数字表法将其分为阿替普酶组(n=40,接受阿替普酶溶栓治疗)和尿激酶组(n=40,接受尿激酶溶栓治疗).对两组患者临床疗效、神经功能缺损、日常生活活动能力、溶栓后相关不良反应发生情况进行统计学分析.结果:治疗后,阿替普酶组患者临床治疗总有效率,高于尿激酶组,差异有统计学意义(P<0.05);阿替普酶组患者《美国国立卫生院卒中量表(NIHSS)》评分低于尿激酶组,Barthel指数高于尿激酶组,差异均有统计学意义(P<0.05).两组患者溶栓后不良反应总发生率比较,差异无统计学意义(P>0.05).结论:阿替普酶与尿激酶溶栓治疗ABI,疗效及安全性均良好,但阿替普酶临床疗效更为突出,在改善神经功能缺损及日常生活活动能力方面尤为明显.Objective:To exploreclinical efficacy and safety of thrombolytic therapy of alteplase and urokinase in patients with acute brain infarction(ABI).Methods:A total of 80 patients with ABI admitted to our hospital from May 2021 to May 2023 were selected as study objects.According to random number table method,they were divided into alteplase group(n=40,receiving alteplase thrombolytic treatment)and urokinase group(n=40,receiving urokinase thrombolysis treatment).The clinical efficacy,nerve function deficit,activities of daily living and overall adverse reactions after thrombolysis were compared between two groups by statistical method.Results:The total effective rate of alteplase group was higher than that of urokinase group,and the difference was statistically significant(P<0.05).After treatment,the score of National Institutes of Health stroke scale(NIHSS)of alteplase group was lower than that of urokinase group,the score of Barthel index was higher than that of urokinase group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in incidence of overall adverse reactions after thrombolysis between two groups(P>0.05).Conclusion:Both alteplase and urokinase have good clinical efficacy and safety in the treatment of patients with ABI,but the alteplase has a more prominent therapeutic effect,especially in improving nerve function defect and activities of daily living.

关 键 词：急性脑梗死 阿替普酶 尿激酶 疗效比较研究 安全性 

分 类 号：R743.33[医药卫生—神经病学与精神病学]